Opendata, web and dolomites

PIONEER SIGNED

Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PIONEER" data sheet

The following table provides information about the project.

Coordinator
STICHTING EUROPEAN UROLOGICAL FOUNDATION 

Organization address
address: Mr. E.N. van Kleffenstraat 5
city: ARNHEM
postcode: 6842 CV
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://prostate-pioneer.eu/
 Total cost 12˙763˙500 €
 EC max contribution 6˙000˙000 € (47%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-10-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2023-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING EUROPEAN UROLOGICAL FOUNDATION NL (ARNHEM) coordinator 400˙000.00
2    ASSOCIATION EISBM FR (VOURLES) participant 700˙000.00
3    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 529˙995.00
4    THE HYVE BV NL (UTRECHT) participant 400˙000.00
5    TAMPEREEN KORKEAKOULUSAATIO SR FI (TAMPERE) participant 387˙500.00
6    THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN UK (ABERDEEN) participant 353˙000.00
7    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 350˙000.00
8    KING'S COLLEGE LONDON UK (LONDON) participant 350˙000.00
9    UNIVERSITA VITA-SALUTE SAN RAFFAELE IT (MILANO) participant 312˙500.00
10    TTOPSTART BV NL (UTRECHT) participant 225˙000.00
11    EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL BE (Brussels) participant 200˙000.00
12    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) participant 200˙000.00
13    LUNDS UNIVERSITET SE (LUND) participant 185˙761.00
14    EUROPEAN ALLIANCE FOR PERSONALISED MEDICINE ASBL BE (BRUXELLES) participant 180˙000.00
15    IHE, INSTITUTET FOR HALSO- OCH SJUKVARDSEKONOMI AKTIEBOLAG SE (LUND) participant 175˙000.00
16    GOETEBORGS UNIVERSITET SE (GOETEBORG) participant 150˙000.00
17    PINSENT MASONS LLP UK (LONDON) participant 150˙000.00
18    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 150˙000.00
19    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 150˙000.00
20    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 125˙000.00
21    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 125˙000.00
22    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 79˙993.00
23    INTERNATIONAL CONSORTIUM FOR HEALTHOUTCOMES MEASUREMENT LTD UK (LONDON) participant 61˙250.00
24    THE ECANCER GLOBAL FOUNDATION UK (BRISTOL) participant 47˙878.00
25    CANCER INTELLIGENCE LIMITED UK (BRISTOL) participant 12˙121.00
26    ASTELLAS PHARMA EUROPE BV NL (LEIDEN) participant 0.00
27    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
28    COVANCE LABORATORIES LTD UK (HARROGATE) participant 0.00
29    IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED UK (LONDON) participant 0.00
30    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
31    NV SAS INSTITUTE SA BE (TERVUREN) participant 0.00
32    ORION OYJ FI (ESPOO) participant 0.00
33    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00
34    TAMPEREEN YLIOPISTO FI (TAMPERE) participant 0.00
35    VARIAN MEDICAL SYSTEM DEUTSCHLAND GMBH DE (DARMSTADT) participant 0.00

Map

 Project objective

Prostate Cancer (PCa) is the second leading cause of cancer, among men in Europe. There are currently major unmet needs in this field, such as insufficient knowledge on risk factors that contribute to PCa and on patient characteristics (including genetic profiles) that could facilitate patient stratification. Finally, there is lack of meaningful engagement of all key stakeholders, while the knowledge currently gained from clinical practice and real life data is not being fed back into PCa patients’ care pathways. There is thus a need for better definition of PCa across all stages, improved patient’s stratification at diagnosis, and standardisation of PCa-related outcomes based on real life data.

PIONEER’s unique dual approach is to first identify critical evidence gaps in PCa by respected Key Opinion Leaders, and then embark on a research priority setting exercise that reflects the needs of all key stakeholders in PCa management. To achieve this, PIONEER has brought together comprehensive datasets that consists of the most relevant prostate clinical trials and registries, large epidemiological cohorts, electronic heath records, and real-life data from different European (and non-European) patient populations. These unique data sets will be integrated, standardised, harmonised and analysed using approaches that are built on our experience of similar previous IMI projects i.e EMIF, and eTRIKS, and analysed using a unique set of methodologies and advanced analytics methods (OMOP, eHS). PIONEER has already performed a first PCa research priority setting survey, where major stakeholders were asked to identify the current unmet needs in PCa. The five most important open questions will be used as pilot studies to verify PIONEER’s research framework. As such, PIONEER’s deliverables will be outcome-driven, value-based and patient-centric, and relevant to all key stakeholders, as they would have been meaningfully involved from the inception of the project.

 Deliverables

List of deliverables.
Policy papers 1/3 Documents, reports 2020-04-25 08:17:27

Take a look to the deliverables list in detail:  detailed list of PIONEER deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PIONEER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PIONEER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

TRIC-TB (2019)

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Read More